BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (August 2019)

24 slides from BioSpecifics Technologies's investor presentation, Aug 22, 2019

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    id 4g “ = @ ‘a? < ne - Innovators in the development & commercialization of: _ INJECTABLE COLLAGENASE c —_ Op. BioSpecifics August 2019

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding

  3. Slide 3: Originator of collagenase based-therapies

    Originator of collagenase based-therapies Positive clinical results for XIAFLEX (collagenase clostridium histolyticum or CCH) reported across multiple indications Profitable biopharma company with lean corporate structure Receives Revenues from XIAFLEX® royalties on net sales, mark-up on COGS, miles

  4. Slide 4: XIAFLEX Pipeline

    XIAFLEX® Pipeline Pract recs | tet | rset | res | tens Dupuytren’s Contracture @endo | Peyronie’s Disease endo E sciiim endo DS Adhesive Capsulits endo EE Human Unome ene = Canine Lipoma anda we Lateral Hip Fat endo, => Plantar Fibromatosis endo E> Uterine Fibroids | Source: Endo International ple

  5. Slide 5: Marketed XIAFLEX Indications: Dupuytren's Contracture & Peyronie's Disease

    Marketed XIAFLEX® Indications: Dupuytren’s Contracture & Peyronie’s Disease

  6. Slide 6: XIAFLEX Marketed Indications Future Growth Opportunities

    XIAFLEX Marketed Indications Future Growth Opportunities Snapshot of XIAFLEX Opportunity Second quarter 2019 BSTC royalty revenues continued to increase year-over- year, 13% growth Endo expects mid-to-high teens percentage range growth for XIAFLEX revenue in 2019 Sizable opportunity for growth Diagn

  7. Slide 7: XIAFLEX for Dupuytren's Contracture

    XIAFLEX® for Dupuytren’s Contracture Definition & Key Complications » Deforming condition of the hand in which one or more fingers contracts toward the palm » Limits range of motion and impairs quality of life Market Opportunity Affects between 3-9% of adult Caucasians * Diagnosis rate of 3%; overal

  8. Slide 8: XIAFLEX for Peyronie's Disease

    XIAFLEX® for Peyronie’s Disease Definition & Key Complications Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with increased pain, painful erections, palpable plaque, penile deformity and erectile dysfunction Potential loss of self

  9. Slide 9: CCH Pipeline Indications

    CCH Pipeline Indications

  10. Slide 10: Overview of CCH for Uterine Fibroids

    Overview of CCH for Uterine Fibroids Definition & Key Complications U.S. Market Opportunity Phase 1 Trial Design Benign tumors in the reproductive tract that contain large amounts of collagen Cause pelvic discomfort and pain, decreased fertility, pregnancy complications, increased rate of miscarriag

  11. Slide 11: Potential Advantages of XIAFLEX

    Potential Advantages of XIAFLEX' Injection vs. Major Surgery Shorter, Easier Process 5-10 minutes vs. 2-4 hours for hysterectomy and myomectomy and 1-2 hours for uterine artery embolization No intubation Sedation vs. anesthesia for surgery Limited Recovery Time “Lost work” costs of $4,500-$30,000 pe

  12. Slide 12: Positive Results from Phase 1 Trial for Uterine Fibroids

    Positive Results from Phase 1 Trial for Uterine Fibroids Positive data presented in March 2019 for BioSpecifics-sponsored clinical trial of CCH for the treatment of uterine fibroids at the 66" Annual Meeting for the Society for Reproductive Investigation Data from 12 patients demonstrated: Statistic

  13. Slide 13: Overview of CCH for Cellulite

    Overview of CCH for Cellulite Definition & Key Complications S. Market Opportunity Phase 3 Trial Design Contour abnormality of the skin resulting in dimpling Skin dimpling caused by tethering of fibrous septae composed of collagen with fat cell volume as secondary cause, occurring mainly on the butt

  14. Slide 14: Positive Top-line Results from Phase 3 Clinical Trials for Cellulite

    Positive Top-line Results from Phase 3 Clinical Trials for Cellulite Top-line results from RELEASE-1 and RELEASE-2 studies announced in November 2018 with additional results presented in May and June 2019; BLA submission expected in the second half of 2019, commercial launch in the second half of 20

  15. Slide 15: Additional Promising Indications

    a Additional Promising Indications BioSpecifics Licensed to Endo In Order of Phase of Development

  16. Slide 16: Human Lipomas

    Human Lipomas Potential to be Only FDA-Approved Pharmaceutical Therapy . Market Opportunity Phase 2 Trial Design Encapsulated deposits of benign fat, often detected as bulges under the skin No FDA-approved pharmaceutical therapies available Offers an alternative to patients that may choose to avoid

  17. Slide 17: Adhesive Capsulitis

    Adhesive Capsulitis Potential to be Only FDA Approved Nonsurgical Therapy Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Common available treatment options are often painful and can require anesthesia Long-term intensive physical therapy, corticost

  18. Slide 18: Plantar Fibromatosis

    Plantar Fibromatosis Definition & Complications ~200,000 patients in the U.S. Pain and disability caused by the thickening of the feet's deep connective tissue Formation of nodules or cords along tendons of the foot Patients often have Dupuytren’s disease, Peyronie’s disease and adhesive capsulitis

  19. Slide 19: Lateral Hip Fat

    Defini Lateral Hip Fat ion & Complications Similar prevalence to cellulite Fat accumulation is common among woman particularly as they age Often very difficult to improve its appearance through exercise and diet alone Patients frequently avoid exercise and are unable to restrict their caloric intake

  20. Slide 20: Endo Partnership for Development and Commercialization of XIAFLEX

    Endo Partnership for Development and Commercialization of XIAFLEX® >$178M Received as of June 30, 2019 Future Payments Due to BioSpecifics from Endo Endo Opt-in Rights Sublicense Income from Endo Partnerships $178M received in licensing, sublicensing, milestone, COGS, and royalty payments as of June

  21. Slide 21: Strong IP Portfolio

    Strong IP Portfolio Dupuytren’s Contracture Biologic Exclusivity until 2022 Drug product composition patent until 2028 Peyronie’s Disease Orphan Drug protection in U.S. until 2020 Drug product composition patent until 2028 Uterine Fibroids Method of use patent until 2034 Patents and Patent Applicati

  22. Slide 22: Consistently Profitable Annually

    Consistently Profitable Annually Financial Highlights (unaudited) For the six months ended 06/30/2019 06/30/2018 Cash and equivalents, and investments $93,509,884 $73,709,882 Income Statement Revenues $16,982,127 $14,940,183 Other income 966,580 588,360 Costs and expenses (4,946,141) (4,520,608) Pro

  23. Slide 23: BioSpecifics Corporate and Clinical Highlights

    BioSpecifics Corporate and Clinical Highlights BioSpecifics continues to be profitable on an ongoing basis BioSpecifics continues to focus on developing CCH for the treatment of medically necessary conditions Additional clinical data from BioSpecifics-sponsored Phase 1 uterine fibroids trial to be p

  24. Slide 24: Innovators in the development & commercialization of injectable collagenase

    f. 4 * 4 ‘a? : - Innovators in the development & commercialization of: _ INJECTABLE COLLAGENASE ea ee, . BioSpecifics August 2019

BioSpecifics Technologies — Investor Presentation (August 2019) on 6ix